Please ensure Javascript is enabled for purposes of website accessibility

The Weaknesses in Sanofi's Diabetes Franchise

By Max Macaluso - Apr 9, 2013 at 6:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

French pharmaceutical company Sanofi is best known for its blockbuster insulin drug Lantus, but can the company maintain its lead in the diabetes market?

French pharmaceutical giant Sanofi (SNY -0.96%) is currently the leader in the long-acting insulin space. Its product Lantus is used by diabetes patients around the world, and it's currently the company's best selling drug. However, what are the challenges up ahead for Sanofi? Will Lantus' multibillion-dollar sales continue in perpetuity? What about Sanofi's other insulin drug Apidra -- is this product a weakness in the company's diabetes franchise?

In the following video, health care analyst Max Macaluso discusses these topics and probes Sanofi's strengths and weaknesses.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
Sanofi
SNY
$52.39 (-0.96%) $0.51

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.